| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2041 | Axicabtagene Ciloleucel | Yescarta | Up to 200 million | Immunotherapy | CAR-T | CD19 | No | 2017 | Jan 1, 2019 | In Use | ||
| NA | Chlorotrianisene | Anisene | 12 mg | Hormonal Therapy | Estrogen | Yes | 1992 | 1997 | In Use | |||
| NA | Leucovorin Calcium | Calcium leucovorin, Lederfoline, Leucosar, Leucovorin rescue, Wellcovorin | 15 mg | Ancillary Therapy | Chemoprotective | Antidote | Yes | 1952 | Jan 1, 1997 | In Use | ||
| J9295 | Necitumumab | Portrazza | 1 mg | Immunotherapy | Monoclonal Antibody | EGFR | No | 2015 | Jan 1, 2017 | In Use | ||
| NA | Nilotinib | Tasigna | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2007 | In Use | |||
| NA | Naldemedine | Symproic | 0.2mg | Ancillary Therapy | Opioid Antagonist | Yes | 2018 | In Use | ||||
| NA | tretinoin | Vesanoid | 10 mg | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Yes | 1995 | In Use | |||
| C9474 | Irinotecan | Onivyde | 1 mg | Chemotherapy | Topoisomerase I Inhibitor | Campothecin Analogs | No | 1996 | Jan 1, 2016 | In Use | ||
| J0896 | Luspatercept | Reblozyl | 0.25mg | Ancillary Therapy | Erythropoiesis-Stimulating Agent | No | 2019 | Jul 1, 2020 | In Use | |||
| J9022 | Atezolizumab | Tecentriq | 10mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2016 | Jan 1, 2018 | In Use | ||
| Q5107 | Bevacizumab-awwb | Mvasi | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2018 | Jan 1, 2019 | In Use | ||
| NA | Zanubrutinib | Brukinsa | 80mg | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Yes | 2019 | In Use | |||
| J9293 | Mitoxantrone | Mitoxantrone | pr 5 mg | Chemotherapy | Antitumor Antibiotic | Anthracenedione | No | 1987 | Jan 1, 1990 | In Use | ||
| NA | ixazomib | Ninlaro | 2.3 mg | Chemotherapy | Proteasome Inhibitor | 20S | Yes | 2015 | In Use | |||
| J9056 | Bendamustine hydrochloride (Vivimusta) | Vivimusta | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2022 | Jul 11, 2023 | In Use | ||
| NA | sonidegib | odozmo | 200 mg | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Yes | 2015 | In Use | |||
| J9999 | Chemotherapy - non specific | Not otherwise classified, antineoplastic drugs | NA | Chemotherapy | No | In Use | ||||||
| S0172 | Chlorambucil | Leukeran | 2 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1957 | Jan 1, 2002 | In Use | ||
| NA | idelalisib | Zydelig | 150 mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2014 | In Use | |||
| J9040 | Bleomycin | Bleomycin | 15 units | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | No | 1973 | Jan 1, 1984 | In Use | ||
| J9039 | Blinatumomab | Blincyto | 1 mcg | Immunotherapy | Monoclonal Antibody | CD3 (T cells) and CD19 (B cells) | No | 2014 | Jan 1, 2016 | In Use | ||
| C9308 | Carboplatin (avyxa) | Kyxata | 1mg | Chemotherapy | Alkylating Agent | Platinum Compound | No | 2025 | Jan 12, 2026 | In Use | ||
| NA | Dacomitinib | Vizimpro | 15mg, 30mg, 45mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2018 | In Use | |||
| J2354 | octreotide | sandostatin | 25 mcg | Hormonal Therapy | Somatostatin Analog | No | 1998 | Jan 1, 2004 | In Use | |||
| C9492 | Durvalumab | Imfinzi | 10 mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2017 | Oct 1, 2017 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home